Downloads
Abstract
Purpose: Describe histopathological characteristics of some common types of non - small cell lung cancer. Determine the expression of PD-L1 in patients with non small cell lung cancer and its relationship with histopathological type, some other factors Methods: 310 patients with non - small cell lung cancer underwent lung tumor biopsy or surgery at the Center for Pathology and Molecular Biology of K Hospital, from the beginning of January 2019 to May 2020, immunohistochemical staining with PD-L1 antibody line Dako PD-L1 IHC 22C3 pharmDx assay.
Results: Adenocarcinoma accounted for the highest rate of 76.5%; squamous cell carcinoma (12.0%). Other histological types account for a very low percentage. Among the adenocarcinoma group, the unclassified adenocarcinoma accounted for the highest rate at 34.6%, the follicular and solid types (24.5% and 23.2%). The rate of PD-L1 positive was 65.8%: low positive was 39.0%, high positive was 26.8%. Adenocarcinoma has a negative, low positive, high positive rate of 35.4%; 38.4%; 26.2%. In squamous cell carcinoma, the rate of negative, low positive, high positive is 37.8%; 45.9%; 16.3%. In the group of high-grade adenocarcinoma, the higher the PD-L1 positive rate. In the squamous cell carcinoma group, the PD-L1-positive non - keratinizing squamous cell carcinoma group was higher than the squamous cell carcinoma group. There was no relationship of PD-L1 ratio with age, sex.
Conclusion: Histopathology of adenocarcinoma, squamous cell carcinoma was the most common. Non - small cell lung cancer has high positive with PD-L1. There was no relationship between the ratio of PD-L1 and age and sex, related to histological grade of adenocarcinoma and subtype of squamous carcinoma.
Keywords: Non - small cell lung cancer, adenocarcinoma, squamous cell carcinoma, PD-L1
References
Ahmedin Jemal D, Tiwari RC, Murray T, et al. Cancer statistics. 2004. 2004;54(1):8-29.
Tsao MS, Kerr KM, Dacic S, et al., IASLC atlas of PDL1 immunohistochemistry testing in lung cancer. 2017:
International Association for the Study of Lung Cancer Aurora, CO.
Polesso F, Weinberg AD, Moran AEJCir. Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 AgonistLarge Tumors Regress with Anti–PD-L1 and AntiOX40 Treatment. 2019;7(2):269-281.
Blank C, Mackensen AJCi, immunotherapy. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. 2007;56:739-745.
Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. 2007;27(1):111-122.
Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. 1999;5(12):1365-1369.
Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients
with advanced urothelial bladder cancer. 2016;34(26):3119.
Yu H, Boyle TA, Zhou C, et al. PD-L1 expression in lung cancer. 2016;11(7):964-975.
Phạm Nguyên Cường, Nghiên cứu phân loại mô bệnh học Ung thư biểu mô phổi theo WHO 2004 và IASLC/ATS/ ERS 2011 có sử dụng dấu ấn hóa mô miễn dịch. 2021.
Younes RN, Deutsch F, Badra C, et al. Nonsmall cell lung cancer: evaluation of 737 consecutive patients in a single institution. 2004;59:119-127.
Trần Thị Tuấn Anh, Lê Trung Thọ, Nguyễn Sỹ Lánh, Trần Thị Thu Hương. Xác định tỷ lệ bộc lộ PD-L1 và đối chiếu với một số đặc điểm của ung thư biểu mô tuyến của phổi. Tạp chí Y học Việt Nam. 2018:471:209-215.
Đoàn Minh Khuy, Phạm Văn Tuyến, Trần Văn Chương. Đánh giá sự bộc lộ của PD-L1 trong bệnh nhân ung
thư phổi không tế bào nhỏ. Tạp chí Y học Việt Nam. 2018:471:152-157.
Urer HN, Kocaturk CI, Gunluoglu MZ, et al. Relationship between lung adenocarcinoma histological subtype and patient prognosis. 2014;20(1):12-18.
Chen Y-b, Mu C-Y, Huang J-AJTJ. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. 2012;98(6):751-755.
Garon E, Rizvi N, Hui R, et al. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer, 10.1056. 2015.
Aggarwal C, Abreu DR, Felip E, et al. Prevalence of PDL1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001,-010, and-024. 2016;27:vi363.
Zhang M, Li G, Wang Y, et al. PD-L1 expression in lung cancer and its correlation with driver mutations: a metaanalysis. 2017;7(1):10255.
Yoneshima Y, Ijichi K, Anai S, et al. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. 2018;118:36-40.
Song Z, Yu X, Cheng G, et al. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. 2016;14(1):1-7.
Driver BR, Miller RA, Miller T, et al. Programmed death ligand-1 (PD-L1) expression in either tumor cells or tumorinfiltrating immune cells correlates with solid and highgrade lung adenocarcinomas. 2017;141(11):1529-1532.
Schoenfeld AJ, Rizvi H, Bandlamudi C, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. 2020;31(5):599-608.
Hirai A, Yoneda K, Shimajiri S, et al. Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I
adenocarcinoma of the lung. 2018;155(1):382-392. e1
| Published | 09-01-2025 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 85 (2023) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.85.6 | |
| Keywords | Từ khóa: Ung thư phổi không tế bào nhỏ, ung thư biểu mô tuyến, ung thư biểu mô vảy, PD-L1 Keywords: Non - small cell lung cancer, adenocarcinoma, squamous cell carcinoma, PD-L1 |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Journal of Clinical Medicine Hue Central Hospital